Caratterizzazione del microbioma tumorale nei sarcomi dei tessuti molli, nelle fibromatosi extra- addominali, nel tumore a cellule giganti e nell’osteosarcoma

Title

Code

TumorMicrobiome

Type

Sperimentale

Start Year

2022

Status

In Corso

Principal Investigator

051-6366566; Fax: 051-6366974

nicola.baldini@ior.it

Baldini Nicola, MD

Director

Biomedical Science and Technologies and Nanobiotechnology Lab

Operational unit that carry out the study

complex unit

Scienze e tecnologie biomediche e nanobiotecnologie

Director

Baldini Nicola, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. TumorMicrobiome

Wednesday 12 October 2022, 16:49

PG0015075_2022_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Caratterizzazione del microbioma tumorale nei sarcomi dei tessuti molli, nelle fibromatosi extra- addominali, nel tumore a cellule giganti e nell’osteosarcoma

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Caratterizzazione del microbioma tumorale nei sarcomi dei tessuti molli, nelle fibromatosi extra- addominali, nel tumore a cellule giganti e nell’osteosarcoma

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in